Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

Part of paid clinical trials in Charleston, South Carolina.

Sponsor
Medical University of South Carolina
Study ID
NCT07697274
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Hyaluronidase (Hylenex) — DRUG
    Patients will receive monthly injections of hyaluronidase into 1 finger on each hand over a 28 week treatment period.

Study Details

Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.

Key Dates

First listed
Jul 13, 2026
Start date
Sep 1, 2026
Status verified
Jul 2026
Primary completion
Sep 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intradermal Hyaluronidase

Primary Outcome Measure

Feasibility Assessment [ Time Frame: 28 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Medical University of South CarolinaCharlestonSouth Carolina29425
Kimberly Hashemi, MD
[email protected]
843-792-9784

Find similar trials in Charleston, SC

By research site
Medical University of South Carolina· Charleston, SC

Related Studies